isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN
申请人:Fibrogen, Inc.
公开号:EP2357175A1
公开(公告)日:2011-08-17
The present invention relates to compounds I suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
[EN] SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF IN MEDICINE<br/>[FR] COMPOSÉ PYRROLIDINE SUBSTITUÉ ET SON UTILISATION EN MÉDECINE<br/>[ZH] 取代的吡咯烷类化合物及其在药物中的应用